Bacteriophage-Based Anti-Infective Companies AmpliPhi Biosciences and Special Phage Services Complete Merger

Published: Nov 13, 2012

RICHMOND, Va. & LONDON & SYDNEY--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (OTCBB: APHB) (“AmpliPhi”) and Special Phage Services (“SPS”) are formally combined following the completion of the share exchange transaction announced on September 10, 2012. Now trading as AmpliPhi, the enlarged company combines complementary technologies and expertise in bacteriophage-based therapies to create an exciting development stage pipeline of innovative anti-bacterials addressing the rapidly growing global market treating antibiotic resistant infections. The transaction was effected through AmpliPhi Australia Pty Limited, a wholly owned subsidiary of US-based AmpliPhi, acquiring 100% of Sydney-based Special Phage Holdings Pty Limited (“SPH”), the holding company of SPS in a share exchange transaction. The combination with AmpliPhi was accepted by 100% of SPH shareholders, and completed following execution of necessary ancillary documents.

Back to news